Biogen (BSP:BIIB34) Days Payable

: 62.49 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

Biogen's average Accounts Payable for the three months ended in Dec. 2023 was R$2,075 Mil. Biogen's Cost of Goods Sold for the three months ended in Dec. 2023 was R$3,030 Mil. Hence, Biogen's Days Payable for the three months ended in Dec. 2023 was 62.49.

The historical rank and industry rank for Biogen's Days Payable or its related term are showing as below:

BSP:BIIB34' s Days Payable Range Over the Past 10 Years
Min: 64.46 Med: 76.29 Max: 99.65
Current: 65.45

During the past 13 years, Biogen's highest Days Payable was 99.65. The lowest was 64.46. And the median was 76.29.

BSP:BIIB34's Days Payable is ranked worse than
63.02% of 979 companies
in the Drug Manufacturers industry
Industry Median: 86.3 vs BSP:BIIB34: 65.45

Biogen's Days Payable declined from Dec. 2022 (69.89) to Dec. 2023 (62.49). It may suggest that Biogen accelerated paying its suppliers.

Biogen Days Payable Historical Data

The historical data trend for Biogen's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

82.26

88.80

86.77

90.25

66.96

Biogen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															69.89	67.88	74.86	60.72	62.49

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biogen Days Payable Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Days Payable distribution charts can be found below:

* The bar in red indicates where Biogen's Days Payable falls into.

Biogen Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Biogen's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (2578.114	+	1976.089)	/	2 )	/	12413.153	*	365
=	2277.1015					/	12413.153	*	365
=	66.96

Biogen's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (2173.522	+	1976.089)	/	2 )	/	3029.547	*	365 / 4
=	2074.8055					/	3029.547	*	365 / 4
=	62.49

Biogen Days Payable Related Terms

Thank you for viewing the detailed overview of Biogen's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (BSP:BIIB34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BSP:BIIB34) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico 1BIIB:Italy IDP:Germany BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (BSP:BIIB34) Headlines

No Headlines